Beicheng Investment is a limited partnership with Betta Investment as the executive partner. Dr. Ding Lieming, the chairman, CEO and actual controller of Betta Pharmaceuticals, Ding Shizhe, a relative of Dr. Ding Shizhe, holds 90% of the shares of Beijia Investment. The total subscribed capital contribution of the institution is RMB 2,000,000,000, of which Betta Pharmaceuticals will contribute RMB 999,000,000 as the LP of the partnership enterprise, and the subscribed capital contribution ratio is 49.95%; The partner (GP) subscribes for a capital contribution of RMB 1 million, and the subscribed capital contribution ratio is 0.05%.
This article is transferred from: https://www.itjuzi.com/fundraising/2577
This site is only for collection, and the copyright belongs to the original author.